Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Immunology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for IMPDH2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IMPDH2 Recombinant Protein (Wild Type & Mutants) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Native tetrameric conformation. |
View IMPDH2 Products |
| Gene Delivery | IMPDH2 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and overexpression validation. |
View IMPDH2 Products |
| Benchmark Ab | Anti-IMPDH2 Recombinant Antibody High-affinity positive control for Western Blot, IHC, and immunoprecipitation. |
View IMPDH2 Products |
| Validator | IMPDH2 siRNA Set For target knockdown and pathway specificity verification. |
View IMPDH2 Products |
| Related Target A | IMPDH1 Highly homologous isoform (84% identity) required for counter-screening to prevent off-target retinal toxicity. |
View IMPDH1 Products |
| Related Target B | GMPS (Guanosine Monophosphate Synthase) Downstream enzyme in the de novo purine synthesis pathway; synergistic target for combination therapy. |
View GMPS Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (IMPDH2 vs. IMPDH1) | Highly purified, sequence-verified IMPDH1 and IMPDH2 recombinant proteins available for high-throughput enzymatic counter-screening. |
| Enzymatic Activity & Aggregation Control | Strict quality control ensuring native tetrameric assembly, verified by size exclusion chromatography (SEC-MALS). |
| Lack of Controls | Sequence-verified benchmark antibodies and validated siRNA pools included for assay calibration. |
| False Positives in Screening | High-purity, endotoxin-controlled preparations minimize background interference in fluorescence-based NADH detection assays. |
Live IMPDH2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IMPDH2 therapeutics is intensifying, with major players shifting focus from traditional broad immunosuppression to targeted oncology and autoimmune applications. As first-generation therapies reach the clinic, the next wave of R&D is targeting selective allosteric inhibition and targeted protein degradation (PROTACs) to overcome systemic toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors (Allosteric) | Academic Institutions, Biotech Startups | Glioblastoma, Hematological Malignancies | High-purity active enzyme for NADH-coupled kinetic assays. |
| PROTACs / Degraders | Kymera Therapeutics, Arvinas (Exploratory) | Solid Tumors, Autoimmune Diseases | Native protein conformation for ternary complex (E3-PROTAC-IMPDH2) formation assays. |
| Immunosuppressants (Classic) | Roche, Novartis | Organ Transplant Rejection, Lupus Nephritis | High-throughput selectivity screening against IMPDH1 to limit side effects. |